why kiss goodbye to the options?
Options expire 20 Dec 2024, placebo results due early 2024.
The new strategy allows the Company to confirm drug efficacy through the
rigor of the placebo-controlled trial design so as to allow for discussion with regulators for potential
fast tracking into registration phase or potential accelerated approval, pending trial outcomes.
Doing the larger study, with potential for a phase 3 outcome would have been possible with massive dilution. Yes, the result would have had a bigger impact, but would it outweight the dilution needed to get there? 680m SOI going to 48c++ after robust data feels just as likely or more than 1.5b shares with essentially the same robust data outcome, both with no guarantee of commercialisation.
why kiss goodbye to the options?Options expire 20 Dec 2024,...
-
- There are more pages in this discussion • 286 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
